748 related articles for article (PubMed ID: 25653511)
1. Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.
Zhang LT; Lee SW; Park K; Chung WS; Kim SW; Hyun JS; Moon DG; Yang SK; Ryu JK; Yang DY; Moon KH; Min KS; Park JK
Clin Interv Aging; 2015; 10():277-86. PubMed ID: 25653511
[TBL] [Abstract][Full Text] [Related]
2. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
[TBL] [Abstract][Full Text] [Related]
3. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
4. Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study.
Cho HJ; Shin SC; Seo DY; Cho JM; Kang JY; Yoo TK; Yu JH; Sung LH; Moon HS
Int J Clin Pract; 2014 Apr; 68(4):471-7. PubMed ID: 24471868
[TBL] [Abstract][Full Text] [Related]
5. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
6. Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
Hwang TI; Chu SH; Lin MS; Chen CS; Lee LM; Chang HC; Yeh SD; Chen WH; Chiang PH
Kaohsiung J Med Sci; 2012 Aug; 28(8):429-34. PubMed ID: 22892164
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Elhilali M; Emberton M; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Alcaraz A; Vallancien G;
BJU Int; 2006 Mar; 97(3):513-9. PubMed ID: 16469018
[TBL] [Abstract][Full Text] [Related]
8. Randomized Controlled Trial to Assess the Efficacy of the Combination Therapy of Alfuzosin and Tadalafil in Patients with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
Kumar S; Kondareddy C; Ganesamoni R; Nanjappa B; Singh SK
Low Urin Tract Symptoms; 2014 Jan; 6(1):35-40. PubMed ID: 26663498
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Roehrborn CG
Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study.
Choo MS; Song M; Kim JH; Lee KS; Kim JC; Kim SW; Yang SK; Lee JG; Lee JZ; Kim DK; Park WH; Kim KD; Na YG; Kwon DD; Paick JS
Urology; 2014 Apr; 83(4):875-81. PubMed ID: 24529580
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Chung BH; Hong SJ
BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
[TBL] [Abstract][Full Text] [Related]
12. [The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)].
Pushkar DY; Loran OB; Bernikov AN
Urologiia; 2022 Dec; (6):21-29. PubMed ID: 36625609
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
14. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
[TBL] [Abstract][Full Text] [Related]
17. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
Vlachopoulos C; Oelke M; Maggi M; Mulhall JP; Rosenberg MT; Brock GB; Esler A; Büttner H
Int J Clin Pract; 2015 Dec; 69(12):1496-507. PubMed ID: 26299520
[TBL] [Abstract][Full Text] [Related]
18. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Kaplan SA; Gonzalez RR; Te AE
Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
[TBL] [Abstract][Full Text] [Related]
19. Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand.
Leungwattanakij S; Watanachote D; Noppakulsatit P; Petchpaibuol T; Choeypunt N; Tongbai T; Wanamkang T; Lojanapiwat B; Permpongkosol S; Tantiwong A; Pripatnanont C; Akarasakul D; Kongwiwatanakul S; Chotikawanich E
J Sex Med; 2010 Sep; 7(9):3115-26. PubMed ID: 20233288
[TBL] [Abstract][Full Text] [Related]
20. Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia.
Bulut S; Ozden C; Aktas BK; Deren T; Tagci S; Gokkaya CS; Baykam MM; Memis A
Urol Int; 2015; 94(2):181-6. PubMed ID: 25139617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
